Roberto Fernández-Acosta

Dr. Roberto Fernández-Acosta

Pharmacy, Institute of Pharmacy and Foods Sciences, University of Havana, Havana, La Habana, Cuba
orcid
Postdoctoral researcher and assistant lecturer

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Roberto Fernández-AcostaRoberto Fernández-Acosta
Roberto Fernández-Acosta
CIClaudia Iriarte-Mesa
Claudia Iriarte-Mesa
DADaniel Alvarez-Alminaque
Daniel Alvarez-Alminaque
BHBehrouz Hassannia
Behrouz Hassannia
BWBartosz Wiernicki
Bartosz Wiernicki
GPGilberto Pardo-Andreu
Gilberto Pardo-Andreu
The use of nanomaterials rationally engineered to treat cancer is a burgeoning field that has reported great medical achievements. Iron-based polymeric nano-formulations with precisely tuned physicochemical properties are an expanding and versatile therapeutic strategy for tumor treatment. Recently, a peculiar type of regulated necrosis named ferroptosis has gained increased attention as a target for cancer therapy. Here, we show for the first time that novel iron oxide nanoparticles coated with gallic acid and polyacrylic acid (IONP–GA/PAA) possess intrinsic cytotoxic activity on various cancer cell lines. Indeed, IONP–GA/PAA treatment efficiently induces ferroptosis in glioblastoma, neuroblastoma, and fibrosarcoma cells. IONP–GA/PAA-induced ferroptosis was blocked by the canonical ferroptosis inhibitors, including deferoxamine and ciclopirox olamine (iron chelators), and ferrostatin-1, the lipophilic radical trap. These ferroptosis inhibitors also prevented the lipid hydroperoxide generation promoted by the nanoparticles. Altogether, we report on novel ferroptosis-inducing iron encapsulated nanoparticles with potent anti-cancer properties, which has promising potential for further in vivo validation.

24 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
Roberto Fernández-AcostaRoberto Fernández-Acosta
Roberto Fernández-Acosta
BHBehrouz Hassannia
Behrouz Hassannia
JCJurgen Caroen
Jurgen Caroen
BWBartosz Wiernicki
Bartosz Wiernicki
DADaniel Alvarez-Alminaque
Daniel Alvarez-Alminaque
GPGilberto Pardo-Andreu
Gilberto Pardo-Andreu
Ferroptosis is an iron-dependent cell death-driven by excessive peroxidation of polyunsaturated fatty acids (PUFAs) of membranes. A growing body of evidence suggests the induction of ferroptosis as a cutting-edge strategy in cancer treatment research. Despite the essential role of mitochondria in cellular metabolism, bioenergetics, and cell death, their function in ferroptosis is still poorly understood. Recently, mitochondria were elucidated as an important component in cysteine-deprivation-induced (CDI) ferroptosis, which provides novel targets in the search for new ferroptosis-inducing compounds (FINs). Here, we identified the natural mitochondrial uncoupler nemorosone as a ferroptosis inducer in cancer cells. Interestingly, nemorosone triggers ferroptosis by a double-edged mechanism. In addition to decreasing the glutathione (GSH) levels by blocking the System xc cystine/glutamate antiporter (SLC7A11), nemorosone increases the intracellular labile Fe2+ pool via heme oxygenase-1 (HMOX1) induction. Interestingly, a structural variant of nemorosone (O-methylated nemorosone), having lost the capacity to uncouple mitochondrial respiration, does not trigger cell death anymore, suggesting that the mitochondrial bioenergetic disruption via mitochondrial uncoupling is necessary for nemorosone-induced ferroptosis. Our results open novel opportunities for cancer cell killing by mitochondrial uncoupling-induced ferroptosis.

2 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MBMariangel Becquer
Mariangel Becquer
AAAdonis Armentero-López
Adonis Armentero-López
DADaniel Alvarez-Almiñaque
Daniel Alvarez-Almiñaque
Roberto Fernández-AcostaRoberto Fernández-Acosta
Roberto Fernández-Acosta
YMYasser Matos-Peralta
Yasser Matos-Peralta
GPGilberto Pardo-Andreu
Gilberto Pardo-Andreu
The disruption of iron homeostasis is an important factor in the loss of mitochondrial function in neural cells, leading to neurodegeneration. Here, we assessed the protective action of gossypitrin (Gos), a naturally occurring flavonoid, on iron-induced neuronal cell damage using mouse hippocampal HT-22 cells and mitochondria isolated from rat brains. Gos was able to rescue HT22 cells from the damage induced by 100 µM Fe(II)-citrate (EC50 8.6 µM). This protection was linked to the prevention of both iron-induced mitochondrial membrane potential dissipation and ATP depletion. In isolated mitochondria, Gos (50 µM) elicited an almost complete protection against iron-induced mitochondrial swelling, the loss of mitochondrial transmembrane potential and ATP depletion. Gos also prevented Fe(II)-citrate-induced mitochondrial lipid peroxidation with an IC50 value (12.45 µM) that was about nine time lower than that for the tert-butylhydroperoxide-induced oxidation. Furthermore, the flavonoid was effective in inhibiting the degradation of both 15 and 1.5 mM 2-deoxyribose. It also decreased Fe(II) concentration with time, while increasing O2 consumption rate, and impairing the reduction of Fe(III) by ascorbate. Gos–Fe(II) complexes were detected by UV-VIS and IR spectroscopies, with an apparent Gos-iron stoichiometry of 2:1. Results suggest that Gos does not generally act as a classical antioxidant, but it directly affects iron, by maintaining it in its ferric form after stimulating Fe(II) oxidation. Metal ions would therefore be unable to participate in a Fenton-type reaction and the lipid peroxidation propagation phase. Hence, Gos could be used to treat neuronal diseases associated with iron-induced oxidative stress and mitochondrial damage.

1 August 2017 in Toxicology in Vitro
Verified
Journal Article
Closed access
JMJavier Marín-Prida
Javier Marín-Prida
GPGilberto Pardo-Andreu
Gilberto Pardo-Andreu
CRCamila Pederiva Rossignoli
Camila Pederiva Rossignoli
MDMichael González Durruthy
Michael González Durruthy
EREstael Ochoa Rodríguez
Estael Ochoa Rodríguez
LALuciane Carla Alberici
Luciane Carla Alberici

26 November 2025 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
IKIne Koeken
Ine Koeken
MWMagali Walravens
Magali Walravens
Roberto Fernández-AcostaRoberto Fernández-Acosta
Roberto Fernández-Acosta
RHRuben Van Hoyweghen
Ruben Van Hoyweghen
IVIuliana Vintea
Iuliana Vintea
TBTom Vanden Berghe
Tom Vanden Berghe
Ferroptosis—an iron-dependent form of cell death triggered by phospholipid peroxidation—has emerged as a promising therapeutic avenue in cancer treatment. Although neuroblastoma (NB) has been identified as a ferroptosis susceptible cancer, our studies reveal striking heterogeneity in ferroptosis sensitivity across high-risk NB models. Through a targeted metabolic compound screen, we identified stearoyl-CoA desaturase 1 (SCD1)—a key enzyme in monounsaturated fatty acid (MUFA) synthesis—as a robust ferroptosis-sensitizing target. Genetic and pharmacological inhibition of SCD1 restored ferroptosis sensitivity in resistant NB cells. Notably, high SCD1 expression correlates with poor patient prognosis. Co-treatment with arachidonic acid (AA), a polyunsaturated fatty acid (PUFA), further enhanced ferroptotic cell death via increased PUFA/MUFA ratio. Nevertheless, neither baseline lipidomic profiles nor transcriptomes of key ferroptosis regulators reliably predicted ferroptosis sensitivity. To overcome AA’s poor solubility, we engineered AA-loaded lipid nanoparticles (AA-LNPs), which selectively accumulated in high-risk NB tumors and synergized with SCD1 inhibition. This dual-sensitization strategy, termed LipidSens, significantly suppressed tumor growth and induced ferroptosis in cell-derived xenograft mouse models without systemic toxicity. Together, these findings establish MUFA synthesis blockade and PUFA enrichment as a tumor-targeted, ferroptosis-enhancing strategy, and offer a nanomedicine-based therapeutic platform for high-risk NB.

10 April 2023 in Phytochemistry
Verified
Journal Article
Closed access
OCOsmany Cuesta-Rubio
Osmany Cuesta-Rubio
LMLianet Monzote
Lianet Monzote
Roberto Fernández-AcostaRoberto Fernández-Acosta
Roberto Fernández-Acosta
GPGilberto Pardo-Andreu
Gilberto Pardo-Andreu
Luca RastrelliLuca Rastrelli
Luca Rastrelli